The European Medicines Agency (EMA) on Thursday approved the coronavirus vaccine from Franco-Austrian biotech Valneva, which becomes the sixth Covid vaccine recommended for adults in the 27 countries of the European Union.
To discover
Taxes 2022: all about your tax return
Read alsoCovid: Valneva's obstacle course
Nantes-based company Valneva is developing an inactivated virus vaccine, a more traditional technology than messenger RNA.
This is also one of the arguments put forward by the laboratory, which believes that this vaccine could convince people who have not yet been vaccinated.
“
The EMA has recommended the granting of a marketing authorization for the vaccine
” Valneva for people “
aged 18 to 50 years old
”, specified the European regulator in a press release.
"
After a thorough assessment, the EMA's Committee for Medicinal Products for Human Use (CHMP) concluded by consensus that the data on the vaccine were robust and met EU criteria for efficacy, safety and efficacy. quality
,” he added.
Valneva has multiplied the disappointments for this vaccine: in September 2021, the British government, which had placed an order for 100 million doses, terminated its contract, a disappointment for the company which had caused its stock price to fall.
In May, it was the turn of the European Union, with which Valneva had an agreement for 60 million doses by 2023, to let it be known that it was considering terminating this order, in a context of significant global production.
Read alsoCovid: Valneva takes a decisive step towards the authorization of its vaccine
In response, Valneva has proposed a plan to try to remedy the situation in an acceptable way and which the European Commission must consider.
Umpteenth episode in this soap opera: last Friday, the biotech called for more orders from European countries for its vaccine in order to be able to maintain this contract.
Five other vaccines have been approved in the European Union: messenger RNA vaccines from the American groups Pfizer and Moderna, those from the Swedish-British laboratory AstraZeneca and its American competitor Johnson & Johnson, which use a viral vector, and the Novavax vaccine.
